Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Psoriasis Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.652

    Miscellaneous Pharmacologic Treatments of Psoriasis

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.652 alerts

    Get alerted when Policy 5.01.652 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity review for selected topical, injectable, and intravenous treatments for plaque psoriasis and generalized pustular psoriasis for Premera commercial plan members. Site-of-service criteria apply to all plan members except Alaska fully insured members.

    Policy Summary
    PayerPremera Bluecross
    PolicyMiscellaneous Pharmacologic Treatments of Psoriasis
    Policy CodePolicy 5.01.652
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 10, 2026
    Next Review DateNot specified
    Key ActionSubmit office visit notes documenting the diagnosis, relevant history, physical evaluation, medication history, and evidence that the applicable medical-necessity criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    HCPCS code J1747 was added for Spevigo (spesolimab-sbzo).

    Coverage criteria for Dovonex (calcipotriene) and Soriatane (acitretin) were removed because the products were discontinued.

    Spevigo subcutaneous coverage criteria were updated to specify treatment of generalized pustular psoriasis when the individual is not experiencing a flare, weighs at least 40 kg, and has a history of at least two moderate-to-severe generalized pustular psoriasis flares.

    Spevigo intravenous criteria were updated to specify a minimum individual weight of 40 kg and reauthorization after prior intravenous treatment for a generalized pustular psoriasis flare with clinical response.

    The age requirement for Zoryve (roflumilast) 0.3% cream for plaque psoriasis was reduced from 6 years to 2 years.

    The policy clarified that site-of-service medical-necessity criteria may apply to injection drugs.

    40 kgSpevigo minimum weight
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Spevigo SC prior flares
    12 monthsNon-Spevigo IV approval period
    1 monthSpevigo IV approval period
    J1747Spevigo HCPCS code

    General Coverage Criteria

    Site-of-service medical necessity

    For individuals age 13 and older subject to site-of-service review, coverage requires a preferred site or a qualifying exception.

    Preferred site or exception

    • Preferred administration site

      • Administration is in a physician office, infusion center, or home infusion.
    • Access or availability exception: No outpatient infusion center is within 50 miles of the individual's home and no contracted home infusion agency will travel to the home; or the hospital is the only place that offers the drug.
    • Increased-risk exception

      • The individual has a known cardiac or pulmonary condition that may increase adverse-reaction risk; unstable renal function limiting response to fluids; difficult or unstable vascular access; an acute mental-status or cognitive condition affecting safety; or a history of severe adverse drug reaction or anaphylaxis to a related or similar drug.
      • The individual has grade 3 or 4 cytokine release syndrome, temperature of at least 38 °C, hypotension requiring one or more vasopressors, and will be admitted to an inpatient setting as soon as possible.

    Topical combination products

    Covered when the applicable product-specific criterion is met.

    Applicable topical product criterion

    • Brand calcipotriene foam or Sorilux is used for plaque psoriasis after inadequate response or intolerance to generic topical calcipotriene.
    • Duobrii is used for plaque psoriasis after inadequate response or intolerance to concurrent generic topical halobetasol and generic topical tazarotene.
    • Enstilar, Taclonex, or Wynzora is used for plaque psoriasis after inadequate response or intolerance to concurrent generic topical betamethasone and generic topical calcipotriene.

    Spevigo IV initial flare therapy

    Spevigo IV may be medically necessary when ALL criteria are met.

    Spevigo IV for GPP flare: The individual is age 12 years or older, weighs at least 40 kg, is experiencing a generalized pustular psoriasis flare, has a GPPPGA total score of at least 3, receives 900 mg by IV infusion with an additional 900 mg dose permitted one week later, and the medication is prescribed by or in consultation with a dermatologist.age >= 12 years; weight >= 40 kg; GPPPGA >= 3; 900 mg IV

    Spevigo IV is subject to site-of-service administration review.

    Spevigo SC maintenance therapy

    Spevigo SC may be medically necessary when ALL criteria are met.

    Spevigo SC for GPP without flare: The individual is age 12 years or older, weighs at least 40 kg, is not experiencing a generalized pustular psoriasis flare, has a history of at least two moderate-to-severe GPP flares, receives 600 mg subcutaneously followed by 300 mg four weeks later and every four weeks thereafter, and the medication is prescribed by or in consultation with a dermatologist.age >= 12 years; weight >= 40 kg; >= 2 prior moderate-to-severe GPP flares; 600 mg then 300 mg at week 4 and every 4 weeks

    Spevigo SC is subject to site-of-service administration review.

    Vtama initial therapy

    Vtama may be medically necessary when ALL criteria are met.

    Vtama for plaque psoriasis: The individual is age 18 years or older, has chronic plaque psoriasis involving at least 3% of body surface area, has an adequate trial and treatment failure with at least one topical corticosteroid unless contraindicated or not tolerated, has an adequate trial and treatment failure with at least one vitamin D analogue unless contraindicated or not tolerated, and the medication is prescribed by or in consultation with a dermatologist.age >= 18 years; BSA >= 3%

    Examples include betamethasone, clobetasol, or mometasone as topical corticosteroids and calcipotriene or calcitriol as vitamin D analogues.

    Zoryve cream initial therapy

    Zoryve cream may be medically necessary when ALL criteria are met.

    Zoryve 0.3% cream for plaque psoriasis: The individual is age 2 years or older, has chronic plaque psoriasis involving at least 2% of body surface area, has an adequate trial and treatment failure with at least one topical corticosteroid unless contraindicated or not tolerated, has an adequate trial and treatment failure with at least one vitamin D analogue unless contraindicated or not tolerated, and the medication is prescribed by or in consultation with a dermatologist.age >= 2 years; BSA >= 2%

    Zoryve foam initial therapy

    Zoryve foam may be medically necessary when ALL criteria are met.

    Zoryve 0.3% foam for plaque psoriasis: The individual is age 12 years or older, has chronic plaque psoriasis involving at least 2% of body surface area, has an adequate trial and treatment failure with at least one topical corticosteroid unless contraindicated or not tolerated, has an adequate trial and treatment failure with at least one vitamin D analogue unless contraindicated or not tolerated, and the medication is prescribed by or in consultation with a dermatologist.age >= 12 years; BSA >= 2%

    FDA dosing requirement

    The medication must be prescribed according to FDA-approved dosage and administration information.

    FDA prescribing information: The medication is prescribed according to the product's US Food and Drug Administration dosage and administration prescribing information.

    Not medically necessary and investigational uses

    The following uses are excluded from medical necessity coverage or are investigational.

    Excluded use

    • The drug is used for an otherwise approved condition but does not meet the policy's listed criteria.

      Not medically necessary.

    • The drug is used in combination with another agent listed in this policy.

      Investigational.

    • The drug is used for a condition not outlined in this policy.

      Investigational.

    Continuation therapy

    Reauthorization requires the drug-specific coverage criteria to remain met and documentation of continued positive clinical response.

    Continuation therapy for drugs other than Spevigo IV: The drug-specific coverage criteria remain met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.approval up to 12 months

    Spevigo IV reauthorization

    Spevigo IV reauthorization may be approved when ALL criteria are met.

    Spevigo IV for a new GPP flare: The individual previously received Spevigo IV treatment for a prior generalized pustular psoriasis flare, achieved clinical response, and is now experiencing a new flare.approval for 1 month

    Spevigo SC initial therapy

    Updated criteria address Spevigo SC treatment of generalized pustular psoriasis when the individual is not experiencing a flare.

    Spevigo SC eligibility: The individual has generalized pustular psoriasis, is not experiencing a flare, weighs at least 40 kg, and has a history of at least two generalized pustular psoriasis flares of moderate-to-severe intensity.weight >= 40 kg; >= 2 prior moderate-to-severe GPP flares

    Spevigo IV initial therapy

    Updated criteria address Spevigo IV treatment of a generalized pustular psoriasis flare.

    Spevigo IV eligibility: The individual weighs at least 40 kg and receives Spevigo IV for a generalized pustular psoriasis flare.weight >= 40 kg

    Spevigo IV continuation therapy

    Updated reauthorization criteria apply to Spevigo IV.

    Spevigo IV reauthorization: The individual previously received Spevigo IV treatment for a prior generalized pustular psoriasis flare and achieved clinical response.prior IV treatment and clinical response

    All other uses of the drugs for approved conditions listed in this policy are considered not medically necessary when the applicable policy criteria are not met.

    Use of the named agents in combination with each other or for conditions not outlined in this policy is considered investigational.

    The site-of-service medical-necessity criteria do not apply to Alaska fully insured members. For these members, apply the infusion and injection drug medical-necessity criteria only. Site-of-service and infusion/injection medical-necessity criteria apply to all other plan members; site-of-service review applies to individuals age 13 and older.

    Coverage criteria for Dovonex (calcipotriene) and Soriatane (acitretin) were removed because these products have been discontinued.

    The manufacturer was not currently seeking FDA approval for spesolimab treatment of palmoplantar pustulosis.

    All other uses of the drugs for approved conditions listed in this policy are considered not medically necessary when the applicable policy criteria are not met.

    Infusion and injectable therapy services are not medically necessary when the applicable site-of-service criteria are not met. For members subject to site-of-service review, preferred sites generally include a physician office, infusion center, or home infusion; hospital-based outpatient administration requires a qualifying exception under the policy.

    Initial Therapy

    Topical product step therapy

    Selected topical products may be medically necessary for plaque psoriasis after the required generic topical therapy.

    Required topical step therapy

    • Before brand calcipotriene foam or Sorilux, the individual tried generic topical calcipotriene and had inadequate response or intolerance.
    • Before Duobrii, the individual tried concurrent generic topical halobetasol and generic topical tazarotene and had inadequate response or intolerance.
    • Before Enstilar, Taclonex, or Wynzora, the individual tried concurrent generic topical betamethasone and generic topical calcipotriene and had inadequate response or intolerance.

    Spevigo IV — generalized pustular psoriasis flare criteria

    Spevigo IV may be considered for generalized pustular psoriasis flare when ALL criteria are met.

    Continuation and Reauthorization

    Continuation for drugs other than Spevigo IV

    All drugs listed other than Spevigo IV may be approved for up to 12 months when continuation criteria are met.

    Continued response: Drug-specific coverage criteria remain met and chart notes demonstrate continued positive clinical response to therapy.approval up to 12 months

    Spevigo IV continuation or retreatment

    Spevigo IV may be reauthorized for 1 month when ALL criteria are met.

    New GPP flare after prior response: The individual previously received Spevigo IV for a prior GPP flare, achieved clinical response, and is now experiencing a new flare.approval for 1 month

    Required Preceding Therapy

    StepRequired prior therapyProducts requiring step therapy
    1Try generic topical calcipotriene and document an inadequate response or intolerance.Brand calcipotriene foam or Sorilux (calcipotriene) foam
    StepRequired prior therapyProduct requiring step therapy
    1Try concurrent generic topical halobetasol and generic topical tazarotene and document an inadequate response or intolerance.Duobrii (halobetasol and tazarotene) lotion
    StepRequired prior therapyProducts requiring step therapy
    1Try concurrent generic topical betamethasone and generic topical calcipotriene and document an inadequate response or intolerance.Enstilar, Taclonex, or Wynzora
    StepRequired prior therapyProducts requiring step therapy
    1Try at least one topical corticosteroid and at least one vitamin D analogue, with an adequate trial and treatment failure, unless contraindicated or not tolerated.Vtama or Zoryve

    Dose and Quantity Limits

    Spevigo IV quantity limit
    Initial dose900 mg by IV infusion
    Optional follow-up doseAn additional 900 mg may be administered one week after the initial dose
    UseTreatment of generalized pustular psoriasis when experiencing a flare
    Spevigo SC quantity limit
    Loading dose600 mg by subcutaneous injection
    First maintenance dose300 mg four weeks after the loading dose
    Ongoing maintenance300 mg every four weeks thereafter

    Administration Site Requirements

    Prior Authorization

    Medical Necessity and Site-of-Service Review

    Providers must complete medical-necessity and site-of-service review for Spevigo (spesolimab-sbzo). IV infusion and injection therapy is covered at the most appropriate, safe, and cost-effective site when the applicable criteria are met.

    • Preferred medically necessary sites are the physician's office, infusion center, and home infusion.
    • Hospital-based outpatient administration is medically necessary only when a listed exception applies.
    Billing Rule

    Infusion Center: Initial and Reinitiated Administration

    The infusion center is the preferred site for Spevigo when available and clinically appropriate. The physician office or home infusion may be used when medically necessary under the applicable site-of-service criteria.

    Coding and Clinical Thresholds

    HCPCS CodeHCPCS
    J1747Injection, spesolimab-sbzo (Spevigo), 1 mg
    Spevigo HCPCS CodeHCPCS
    J1747HCPCS code for Spevigo (spesolimab-sbzo)
    Spevigo IV weight threshold
    Minimum weightAt least 40 kg
    TreatmentSpevigo IV for generalized pustular psoriasis when experiencing a flare
    Age requirementAge 12 years or older
    Spevigo IV GPPPGA threshold
    Minimum GPPPGA scoreAt least 3
    Severity levelModerate
    AssessmentGeneralized Pustular Psoriasis Physician Global Assessment total score

    Prior Authorization and Documentation

    Prior Authorization

    Obtain prior authorization and site review

    Submit prior authorization for the listed drugs so medical necessity can be reviewed. Spevigo IV and SC are subject to site-of-service administration review; Spevigo IV is reviewed for medical necessity for all ages, while site-of-service review applies to individuals age 13 and older.

    • Use HCPCS J1747 for injection, spesolimab-sbzo (Spevigo), 1 mg.
    • Site-of-service criteria do not apply to Alaska fully insured members; those members are directed to the infusion and injection drug medical-necessity criteria only.
    Step Therapy

    Try required generic topical alternatives

    Before requesting brand calcipotriene foam or Sorilux, document an inadequate response or intolerance to generic topical calcipotriene. Before requesting Duobrii, document an inadequate response or intolerance to concurrent generic topical halobetasol and generic topical tazarotene.

    • Brand calcipotriene foam or Sorilux: try generic topical calcipotriene first.
    • Duobrii: try concurrent generic topical halobetasol and generic topical tazarotene first.

    Condition and Treatment Background

    Psoriasis is an inflammatory skin condition that causes red, scaly plaques and may occur anywhere on the body. Treatment often begins with topical therapy; light therapy or oral and injectable drugs may be considered when topical treatment is inadequate or when the disease affects a large area. This policy addresses selected treatments for plaque psoriasis and generalized pustular psoriasis, including treatment of acute generalized pustular psoriasis flares.

    Definitions and Clinical Terms

    GPPPGA
    Full nameGeneralized Pustular Psoriasis Physician Global Assessment
    Scoring range0 (clear) to 4 (severe)
    Moderate-to-severe thresholdA total score of at least 3
    Site of service
    DefinitionThe location where a drug is administered
    Covered locationsHospital-based outpatient setting, infusion center, physician's office, or home
    Review ageSite-of-service medical-necessity review applies to individuals age 13 and older
    Policy Summary
    PayerPremera Bluecross
    PolicyMiscellaneous Pharmacologic Treatments of Psoriasis
    Policy CodePolicy 5.01.652
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 10, 2026
    Next Review DateNot specified
    Key ActionSubmit office visit notes documenting the diagnosis, relevant history, physical evaluation, medication history, and evidence that the applicable medical-necessity criteria are met.
    SourceLink
    On This Page
    General Coverage CriteriaInitial TherapyContinuation and ReauthorizationRequired Preceding TherapyDose and Quantity LimitsAdministration Site RequirementsCoding and Clinical ThresholdsPrior Authorization and DocumentationCondition and Treatment BackgroundDefinitions and Clinical Terms
    Spevigo IV: The individual is age 12 years or older, weighs at least 40 kg, is experiencing a GPP flare, has a GPPPGA total score of at least 3, receives 900 mg IV with an optional additional 900 mg one week later, and the medication is prescribed by or in consultation with a dermatologist.age >= 12 years; weight >= 40 kg; GPPPGA >= 3

    Spevigo SC — generalized pustular psoriasis without flare criteria

    Spevigo SC may be considered for generalized pustular psoriasis without flare when ALL criteria are met.

    Spevigo SC: The individual is age 12 years or older, weighs at least 40 kg, is not experiencing a flare, has a history of at least two moderate-to-severe GPP flares, receives 600 mg subcutaneously followed by 300 mg at week 4 and every 4 weeks, and the medication is prescribed by or in consultation with a dermatologist.age >= 12 years; weight >= 40 kg; >= 2 prior moderate-to-severe GPP flares

    Vtama — plaque psoriasis criteria

    Vtama may be considered for plaque psoriasis when ALL criteria are met.

    Vtama: The individual is age 18 years or older, has chronic plaque psoriasis involving at least 3% BSA, has failed an adequate trial of at least one topical corticosteroid and at least one vitamin D analogue unless contraindicated or not tolerated, and the medication is prescribed by or in consultation with a dermatologist.age >= 18 years; BSA >= 3%

    Zoryve — cream or foam plaque psoriasis criteria

    Zoryve cream or foam may be considered for plaque psoriasis when ALL criteria are met.

    Zoryve: For cream, the individual is age 2 years or older; for foam, age 12 years or older; the individual has chronic plaque psoriasis involving at least 2% BSA; has failed an adequate trial of at least one topical corticosteroid and at least one vitamin D analogue unless contraindicated or not tolerated; and the medication is prescribed by or in consultation with a dermatologist.cream age >= 2 years; foam age >= 12 years; BSA >= 2%

    Spevigo SC — updated criteria for generalized pustular psoriasis without flare

    Updated criteria apply to Spevigo SC for generalized pustular psoriasis without flare.

    Spevigo SC: The individual has generalized pustular psoriasis, is not experiencing a flare, weighs at least 40 kg, and has a history of at least two generalized pustular psoriasis flares of moderate-to-severe intensity.weight >= 40 kg; >= 2 prior moderate-to-severe GPP flares

    Spevigo IV — updated minimum-weight criterion

    Updated Spevigo IV criteria include a minimum weight requirement.

    Minimum-weight requirement: The individual weighs at least 40 kg and is being treated with Spevigo IV for a generalized pustular psoriasis flare.weight >= 40 kg

    Spevigo IV continuation — updated reauthorization criteria

    Updated reauthorization criteria apply to Spevigo IV.

    Spevigo IV reauthorization: The individual previously received Spevigo IV treatment for a prior generalized pustular psoriasis flare and achieved clinical response.prior IV treatment; clinical response
    • The initial course of infusion or injection is considered medically necessary at the effective site for the first 90 days.
    • Re-initiation after a discontinuation of 6 months or longer is considered medically necessary at the effective site; this does not apply when standard dosing between administrations is 6 months or longer.
    • Use the applicable coverage and site-of-service criteria when a requested circumstance falls outside the situations listed in this section.
    • For an unlisted combination of conditions or other unlisted circumstance, submit documentation supporting medical necessity for the requested site and treatment.
    Note

    Home Infusion Preferred When Appropriate

    Home infusion is the preferred site when it is safely and appropriately available for the individual. Home infusion may be used when a contracted agency can provide the required therapy and clinical monitoring in the home.

    • Home infusion is not required when it is clinically unsafe or inappropriate.
    • Hospital-based administration may be considered when no outpatient infusion center is within 50 miles of the individual's home and no contracted home infusion agency will travel to the home.
    Documentation Required

    Hospital Outpatient: Increased-Risk Conditions

    Hospital-based outpatient administration is medically necessary only when the individual has a clinical condition that increases the risk of complications from infusion or injection, or when the hospital is the only available site under the applicable criteria.

    • Qualifying conditions include a known cardiac or pulmonary condition that may increase adverse-reaction risk; unstable renal function that decreases the ability to respond to fluids; difficult or unstable vascular access; acute mental-status changes or cognitive conditions affecting treatment safety; or a history of severe adverse drug reactions or anaphylaxis to a related or similar drug.
    • Permitted hospital sites include a hospital-based outpatient setting, outpatient hospital IV infusion department, or hospital-based outpatient clinical level of care.
    • Document the qualifying condition and explain why hospital-based administration is required.
    • For Spevigo, include clinical documentation supporting the diagnosis, indication, dosing, treatment history, prior response or adverse reactions, and the requested administration site.
    • Submit documentation of required prior topical treatment failures when those failures are part of the applicable coverage criteria.

    Unsupported block type: denial_risk terset_draft?

    Note

    Office: Injection Drug Site-of-Service Review

    The site-of-service medical-necessity criteria may apply to injection drugs, not only intravenous infusion therapy. Providers should apply the applicable criteria to Spevigo and other covered injection drugs and document the medical necessity of the requested administration site.

    • Sites that do not meet the applicable site-of-service criteria are not medically necessary for infusion or injectable therapy services.
    • Use criteria outside the listed examples only when the applicable policy requirements are met and the clinical rationale is documented.
    Spevigo SC prior flare history
    Prior flare historyAt least 2 generalized pustular psoriasis flares
    Required severityModerate-to-severe intensity
    Current statusThe individual is not experiencing a flare
    Vtama plaque psoriasis threshold
    Minimum affected areaAt least 3% of body surface area
    ConditionChronic plaque psoriasis
    TreatmentVtama (tapinarof) cream
    Zoryve plaque psoriasis threshold
    Minimum affected areaAt least 2% of body surface area
    ConditionChronic plaque psoriasis
    ProductsZoryve (roflumilast) 0.3% cream or foam
    Distance to outpatient infusion
    Distance thresholdNo outpatient infusion center within 50 miles of the individual's home
    Additional requirementNo contracted home infusion agency will travel to the individual's home
    Alternative exceptionA hospital is the only place that offers infusions or injections of the drug
    GPPGA pustulation subscore threshold
    Minimum pustulation subscoreAt least 2
    AssessmentGPPGA pustulation subscore
    Clinical contextDefines a current moderate-to-severe generalized pustular psoriasis flare in the cited study
    GPP body-surface-area involvement
    Minimum BSA involvementAt least 5%
    ConditionGeneralized pustular psoriasis
    Clinical contextPart of the cited study definition of a current moderate-to-severe flare
    GPP flare total-score increase
    Required increaseAt least 2 points from baseline
    MeasureGPPPGA total score
    Clinical contextUsed in the cited study definition of recurrence of a generalized pustular psoriasis flare after a score of 0 or 1 had been achieved
    GPP flare pustulation subscore
    Minimum pustulation subscoreAt least 2
    MeasureGPPPGA pustulation subscore
    Clinical contextCombined with an increase in the GPPPGA total score of at least 2 points from baseline to define a GPP flare in the cited study
    Step Therapy

    Try concurrent generic alternatives

    Before requesting Enstilar, Taclonex, or Wynzora, document an inadequate response or intolerance to concurrent generic topical betamethasone and generic topical calcipotriene.

    • The generic alternatives must be used concurrently.
    • Document inadequate response or intolerance.
    Step Therapy

    Document topical treatment failures

    Before requesting Vtama or Zoryve, document an adequate trial and treatment failure with at least one topical corticosteroid and at least one vitamin D analogue. The trial may be omitted when the treatment is contraindicated or not tolerated.

    • Examples of topical corticosteroids include betamethasone, clobetasol, and mometasone.
    • Examples of vitamin D analogues include calcipotriene and calcitriol.
    Documentation Required

    Submit complete clinical records

    Submit office visit notes documenting the diagnosis, relevant history, physical evaluation, medication history, and evidence that the applicable medical-necessity criteria are met.

    • Records should support the requested drug and indication.
    • Include the clinical evidence needed for the applicable drug-specific criteria.
    Documentation Required

    Document Spevigo eligibility

    For Spevigo, submit documentation supporting the individual’s age, weight, current flare status or prior flare history, GPPPGA score when applicable, prescribed dose, and prescribing by or consultation with a dermatologist.

    • Spevigo IV requires documentation of weight of at least 40 kg, an active GPP flare, GPPPGA total score of at least 3, and a 900 mg IV dose.
    • Spevigo SC requires weight of at least 40 kg, no current flare, and a history of at least two moderate-to-severe GPP flares.
    Documentation Required

    Document topical nonsteroidal criteria

    For Vtama and Zoryve, document age, chronic plaque psoriasis, affected body-surface area, adequate trials and treatment failures with a topical corticosteroid and a vitamin D analogue, and prescribing by or consultation with a dermatologist.

    • Vtama requires plaque psoriasis involving at least 3% BSA.
    • Zoryve requires plaque psoriasis involving at least 2% BSA; the cream is available for individuals age 2 years or older and the foam for individuals age 12 years or older.
    Denial Risk

    Avoid uses outside listed criteria

    Do not request the named agents for uses outside the conditions and criteria listed in the policy. All other uses of the drugs for approved conditions listed in the policy are considered not medically necessary.

    • Coverage requires the applicable drug-specific criteria to be met.
    Denial Risk

    Avoid unlisted combinations and conditions

    Do not use the named agents in combination with each other or for conditions not outlined in the policy. Such use is considered investigational.

    • Combination use of the named agents is investigational.
    • Use for an unlisted condition is investigational.
    Denial Risk

    Meet all drug-specific criteria

    Coverage may be denied when the applicable drug-specific age, diagnosis, disease-severity, prior-treatment, dosing, prescriber, or response criteria are not met. Verify and document every applicable criterion before submitting the request.

    • Use the product’s US FDA dosage and administration information.
    • Document required treatment trials, treatment response or failure, and dermatologist prescribing or consultation when applicable.
    Denial Risk

    Use an approved site of service

    For members subject to site-of-service review, infusion or injection therapy is not medically necessary when the policy’s site-of-service criteria are not met. Submit the applicable preferred-site information or document a qualifying exception.

    • Preferred sites are the physician office, infusion center, and home infusion.
    • Hospital-based outpatient administration requires a listed exception, such as a qualifying increased-risk condition or severe CRS exception.
    Grade 3 or 4 CRS
    CRS gradeGrade 3 or 4
    Temperature findingAt least 38 °C
    Hemodynamic findingHypotension requiring one or more vasopressors
    Generalized pustular psoriasis
    Disease typeA rare, multisystem form of pustular psoriasis
    Skin findingSterile, visible pustules on non-acral skin
    Associated conditionsMay occur with or without systemic inflammation or psoriasis vulgaris
    Palmoplantar pustulosis
    Skin findingSterile, visible pustules on the palms and soles
    DurationPersistent for more than 3 months
    ClassificationA pustular psoriasis subtype described in the policy
    Acrodermatitis continua of Hallopeau
    Skin findingSterile, visible pustules affecting the nails
    DurationPersistent for more than 3 months
    ClassificationA pustular psoriasis subtype described in the policy
    GPP flare
    Pustulation criterionGPPGA pustulation subscore of at least 2
    Disease-assessment criterionGPPGA total score increase of at least 2 points from baseline
    Study-based definitionThe prevention study defined a flare using both thresholds